Additionally, the findings of the DAPA-HF trial raise serious doubts about the validity of current assumptions about the physiological mechanisms that have been proposed to explain the benefits of SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is hydrops fetalis.